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Objective: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers. 
Since αvβ6 integrin has been reported as a promising target for PDAC diagnosis, we 
previously developed H-Cys(mal-NOTA-67Ga)-(Gly)6-A20FMDV2-NH2 ([
67Ga]CG6) 
as an αvβ6 integrin-targeting probe. Although [67Ga]CG6 specifically binds to αvβ6 
integrin-positive xenografts, the uptake of [67Ga]CG6 in the organs surrounding the 
pancreas, such as the liver and spleen, was comparable to that in the αvβ6 
integrin-positive xenografts. We hypothesized that the undesirable accumulation of 
[67Ga]CG6 in those organs was caused by the positive charges of [67Ga]CG6 (+3). In 
this study, we aimed to decrease [67Ga]CG6 uptake in the liver and spleen by reducing 
the electric charges of the probe. 
Methods: We synthesized H-Cys(mal-NOTA-67Ga)-(Asp)6-A20FMDV2-NH2 
([67Ga]CD6) and evaluated its affinity to αvβ6 integrin via in vitro competitive binding 
assay. Isoelectric points of the probes were determined by electrophoresis. 
Biodistribution study, autoradiography, and immunostaining for β6 integrin were 
conducted using αvβ6 integrin-positive and negative tumor-bearing mice. 
Results: In vitro competitive binding assay showed that the alteration of the linker had a 
negligible impact on the affinity of [67Ga]CG6 to αvβ6 integrin. The results of 




electrophoresis revealed that [67Ga]CG6 was positively charged whereas [67Ga]CD6 
was negatively charged. In the biodistribution study, the uptake of [67Ga]CD6 in the 
αvβ6 integrin-positive xenografts was significantly higher than that in the αvβ6 
integrin-negative ones at 60 and 120 minutes. The uptake of [67Ga]CD6 in the liver and 
spleen was more than 2-fold lower than that of [67Ga]CG6 at both time points. In the 
immunohistochemistry study, the radioactivity accumulated areas in the autoradiogram 
of the αvβ6 integrin-positive xenograft coincided with β6 integrin-expressing areas. 
Conclusion: We have successfully reduced the nonspecific uptake in the liver and 
spleen by altering the linker amino acid from G6 to D6. [67Ga]CD6 overcame the 
drawbacks of [67Ga]CG6 in its biodistribution. 
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Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant 
cancers in humans, and is a major cause of cancer-related deaths [1]. Despite recent 
medical developments, it is difficult to develop new effective therapies, and hence 
PDAC is expected to become the second leading cause of cancer deaths by 2030 [2]. 
Under current circumstances, the most effective treatment for PDAC is surgical 
resection, and therefore it is thought that early detection of PDAC closely correlates 
with a patient’s prognosis. However, the initial symptoms of PDAC lack specific 
clinical features, therefore, it is challenging to detect PDAC at an operable stage [3]. 
An epithelial-specific cell surface receptor, αvβ6 integrin, is usually 
undetectable in healthy adult tissues. The expression of αvβ6 integrin, however, is 
significantly upregulated in many malignant cancers, and αvβ6 integrin is involved in 
the migration, invasion, and proliferation of tumor cells [4-9]. Previously, it was 
reported that almost all PDAC patients had positive αvβ6 integrin expression, and the 
significant upregulation of αvβ6 integrin in PDAC was closely related to the 
malignancy of PDAC [5, 10]. Willemieke et al. previously reported that αvβ6 integrin 
was an excellent biomarker to differentiate PDAC from other tissues and to identify 
tumor-positive lymph nodes [11]. Due to this data, we focused on αvβ6 integrin as a 




promising target for both the prognosis and detection of PDAC. 
A20FMDV2 (NAVPNLRGDLQVLAQKVART) is a 20-amino acid peptide 
derived from an envelope protein of the foot-and-mouth disease virus [12]. A20FMDV2 
shows a high affinity and selectivity to αvβ6 integrin [13], therefore this peptide has 
been used for positron emission tomography (PET) and single-photon emission 
computed tomography (SPECT) imaging studies such as 
[18F]FBA-PEG28-A20FMDV2-PEG28 [14], 64Cu-labeled A20FMDV2 [15], 
[123I]IFMDV2 [3], and [111In]DTPA-A20FMDV2 [16]. In our previous study, we 
focused on gallium-68 (T1/2 = 68 minutes) because it is a generator-produced 
radionuclide and does not require a cyclotron on site, unlike fluorine-18 and copper-64. 
In order to develop a 68Ga-labeled A20FMDV2 peptide, we synthesized 
H-Cys(mal-NOTA-natGa)-(Gly)n-A20FMDV2-NH2 (n = 1, 4, 6, 8), and discovered that 
the G6 linker (n = 6) was the most appropriate length not to hamper the binding of the 
peptide to αvβ6 integrin between the N-terminus of A20FMDV2 and the cysteine 
residue which was conjugated with maleimide-NOTA. The 
H-Cys(mal-NOTA-67Ga)-(Gly)6-A20FMDV2-NH2 (termed [
67Ga]CG6) showed high 
affinity and specificity to αvβ6 integrin in vivo [17]. However, [67Ga]CG6 tended to 
accumulate in the organs surrounding the pancreas, such as the liver and spleen, at the 




same level as αvβ6 integrin-positive xenografts, hence, it seemed that [67Ga]CG6 was 
not suitable for the diagnosis of the primary PDAC. 
We hypothesized that the undesirable accumulation of [67Ga]CG6 in those 
organs was caused by the positive charges of [67Ga]CG6, since the theoretical charge of 
the probe was +3. In this study, we designed and synthesized 
H-Cys(mal-NOTA-67Ga)-(Asp)6-A20FMDV2-NH2 (termed [
67Ga]CD6) containing the 
D6 linker, instead of the G6 linker, to reduce the positive charge of [67Ga]CG6. We 
aimed to evaluate the utility of [67Ga]CD6 as an αvβ6 integrin imaging agent and 
compare the biodistribution of [67Ga]CG6 with that of [67Ga]CD6. 
 
 
Materials and Methods 
General 
 The 9-fluorenylmethyloxycarbonyl (Fmoc)-protected amino acids, 
Fmoc-NH-SAL-MBHA Resin, and coupling agents 
(O-(1H-benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate, 
1-hydroxy-1H-benzotriazole hydrate, and N,N-diisopropylethylamine) were purchased 
from Watanabe Chemical Industries, Ltd. (Hiroshima, Japan). 





azonane-1,4-diyl)diacetic acid (maleimide-NOTA) was purchased from CheMatech 
(Dijon, France). Gallium-67 chloride was kindly supplied and gallium-67 citrate was 
purchased from FUJIFILM Toyama Chemical Co., Ltd. (Tokyo, Japan). Immobiline 
DryStrip pH3-11 (7 cm) and the IPG buffer pH3-11 were purchased from GE 
Healthcare (Boston, USA). Reversed-phase high-performance liquid chromatography 
(RP-HPLC) was performed on a Cosmosil 5C18-AR-II column (4.6 × 150 mm for 
analytical RP-HPLC and 10 × 250 mm for preparative RP-HPLC; Nacalai Tesque, Inc., 
Kyoto, Japan) using a 28% v/v acetonitrile in 0.1% v/v trifluoroacetic acid/H2O as a 
mobile phase at a flow rate of 1.0 mL/min for analytical RP-HPLC and 4.0 mL/min for 
preparative RP-HPLC. The eluate was monitored via the detection of its proper 
absorption at 220-230 nm. 
Animal experiments were performed in accordance with the guidelines of the 
Okayama University Animal Care Committee. The experimental procedures performed 
were approved by the committee. 
 
Peptide synthesis and maleimide-NOTA conjugation 
Peptides were synthesized by Fmoc solid-phase peptide synthesis using an 




automated peptide synthesizer (PSSM-8; Shimadzu Corporation, Kyoto, Japan) 
according to a previously described method [18]. These peptides were extended using 
Fmoc-NH-SAL-MBHA Resin as a starting material. The crude peptides were purified 
by preparative RP-HPLC before lyophilization. 
Maleimide-NOTA was incubated with purified peptides in a 0.2 M ammonium 
acetate buffer (pH 6.5, 100 µL) at room temperature for 60 minutes. The crude 
NOTA-peptides were also purified by preparative RP-HPLC before lyophilization. 
 To obtain nonradioactive authentic probes, the purified NOTA-peptides were 
incubated with Ga(NO3)3 in 100 µL of water at 80ºC for 15 minutes. The crude 
Ga-NOTA-peptides were purified via preparative RP-HPLC before lyophilization. 
The identities below were determined by analytical RP-HPLC and electrospray 
ionization mass spectroscopy (API4000; SCIEX, Framingham, MA).  
 
[natGa]CG6: calculated for C126H212GaN44O41S [M+3H]
3+; m/z, 1034.5; found, 1035.2. 
[natGa]CD6: calculated for C138H224GaN44O53S [M+3H]
3+; m/z, 1150.5; found, 1151.0. 
 
Cells and Cell culture 
 AsPC-1 and MIA PaCa-2 human pancreatic carcinoma cells were obtained 




from the European Collection of Authenticated Cell Cultures and the RIKEN BRC Cell 
Engineering Division, respectively. Both cells were cultured as previously described 
[17]. 
 
Competitive binding assay 
 The affinity of [natGa]CD6 to αvβ6 integrin was evaluated by competitive 
binding assay using [125I]IFMDV2 as a radioligand (n = 4). The Ki value of [natGa]CD6 
was calculated by using GraphPad Prism 7 (GraphPad Software, Inc., San Diego, CA). 
Preparation of [125I]IFMDV2 and binding assay were conducted according to a 
previously described method [3]. 
 
Isoelectric point evaluation 
 The purified peptides (100-200 µg) were dissolved in 125 µL sample buffer (8 
M urea, 20% v/v glycerol, 0.5% IPG buffer) and an Immobiline Dry strip was saturated 
with the solution. Electrophoresis was performed in four steps (1. Hold [300 V, 30 
minutes], 2. Gradient [1,000 V, 30 minutes], 3. Gradient [5,000 V, 80 minutes], 4. Hold 
[5,000V, 25 minutes]) on Ettan IPGphor 3 (GE Healthcare). Immobilization of the 
peptides in the gels was performed with 12.5% v/v glutaraldehyde/H2O for 60 minutes, 




and the gels were washed 3 times with washing buffer (30% v/v methanol and 10% v/v 
acetic acid in water). Thereafter, the gels were stained by Coomassie brilliant blue 
(CBB) solution (0.02% w/v CBB and 0.10% w/v copper sulfate in washing buffer) for 
60 minutes, and were then washed 3 times with washing buffer. The bands derived from 
the peptides in the gels were detected by Chemidoc XRS (Bio-Rad Laboratories, Inc., 
Hercules, USA). The pI values were determined according to the manufacturer’s 
protocol. 
 The pI values of both peptides containing non-amidated C-terminus were 
calculated by the ProtParam tool (http://web.expasy.org/protparam/). 
 
Radiolabeling 
 The purified NOTA-peptides (20-40 µg) were incubated with 67GaCl3 or 
67Ga-citrate (2-15 MBq) in 0.2 M sodium acetate buffer (100-300 µL, pH 4.0) at 80ºC 
for 15 minutes. The reaction solution was then purified by analytical RP-HPLC. 
 
Log P determination 
[67Ga]CG6 or [67Ga]CD6 was added into an equal volume (500 µL:500 µL) 
mixture of n-octanol and 25 mM phosphate buffer (pH7.4). After vigorous shaking for 




30 minutes, the mixture was centrifuged at 5,000 rpm for 5 minutes. Samples from both 
n-octanol and aqueous layers were obtained, and their radioactivity was measured. The 
partition coefficients (log P-values) were calculated as the average of three independent 
measurements. 
 
In vitro plasma stability evaluation 
 Preparation of the rodent plasma and stability evaluation of [67Ga]CD6 were 
performed according to a previously described method [17]. 
 
Animal model 
 Male severe combined immunodeficiency mice (C.B-17/Icr-scid Jcl) at 4 
weeks of age were purchased from CLEA Japan, Inc. (Tokyo, Japan). Models of 




 [67Ga]CG6 or [67Ga]CD6 (100 kBq/100 µL) were injected intravenously into 
tumor bearing mice (n = 3-8) in the tail vein. The mice were killed at 10, 60, and 120 




minutes after probe administration. Whole organs were immediately harvested and 
weighed, and their radioactivity was measured. The results were expressed as the 
percentage injected dose per gram (%ID/g). 
 
Autoradiography and Immunostaining 
 [67Ga]CD6 (1.5 MBq/100 µL) was injected intravenously into tumor bearing 
mice (n = 4) in the tail vein, and the mice were killed 60 minutes after probe 
administration. The tumors were removed and frozen in hexane (-80ºC), and the frozen 
tumors were sliced into 10 µm-thick sections with a cryomicrotome (CM1860; Leica 
Microsystems, Wetzlar, Germany). The sections were exposed to an imaging plate for 
20 hours, and autoradiograms were obtained with a Typhoon FLA 7000 (GE Healthcare). 
The adjacent sections used for autoradiography were incubated with 1:100 diluted 
anti-β6 integrin mAb (Millipore, Burlington, USA) at 4ºC for 12 hours as a primary 
antibody. After incubation, these sections were incubated with 1:200 diluted anti-mouse 
IgG, horseradish peroxidase-linked whole antibody (GE Healthcare) at 4ºC for 12 hours. 
Finally, DAB and hematoxylin staining were performed. Photo data were acquired using 
an Olympus BX53 microscope (Olympus Corporation, Tokyo, Japan). 
 





 The data are expressed as mean ± standard deviation. The Mann Whitney 
U-test was performed by using GraphPad Prism 7 to evaluate statistical significance. A 




Binding affinity to αvβ6 integrin 
 The calculated Ki value of [67Ga]CD6 was 4.4 ± 2.0 nM, and was comparable 
to that of [67Ga]CG6 (3.5 ± 0.3 nM [17]). This finding indicated that the linker alteration 
from G6 to D6 had a negligible impact on the binding affinity to αvβ6 integrin. 
 
Isoelectric point evaluation 
 Pictures of CBB stained gels are shown in Fig. 1. The band of 
CG6-A20FMDV2 was detected at the anode side, and that of CD6-A20FMDV2 was 
detected at the cathode side. The calculated and measured pI values are shown in Table 
1. It was confirmed that CG6-A20FMDV2 was positively charged and 
CD6-A20FMDV2 was negatively charged. There were slight differences between the 




measured pI values and the calculated ones. We used C-terminal amidated peptides for 
pI determination, however the ProtParam tool cannot calculate pI values of peptides 
containing modified amino acids. Therefore, the measured pI values are more basic than 
the calculated values. 
 
Radiolabeling 
 Analytical HPLC chromatograms of [nat/67Ga]CG6 and [nat/67Ga]CD6 are shown 
in Fig. 2. The radiochemical yield of [67Ga]CG6 and [67Ga]CD6 was 55-69%. The 
radiochemical purity of both probes was > 95%. 
 
Log P determination 
 The Log P-values of [67Ga]CG6 and [67Ga]CD6 were -2.96 ± 0.14 and -2.88 ± 
0.26, respectively. 
 
In vitro stability evaluation 
 The extraction rate of radioactivity from the plasma was 53.0 ± 3.0%. The 
recovery of radioactivity from the HPLC column was 87.2 ± 0.7%. The percentages of 
intact [67Ga]CD6 at 60 and 120 minutes were 86.7 ± 1.0% and 71.4 ± 5.7%, 







 Biodistribution of each probe was evaluated in mice bearing AsPC-1 (αvβ6 
integrin positive) and MIA PaCa-2 (αvβ6 integrin negative) xenografts. The results are 
shown in Table 2. Biodistribution data of [67Ga]CG6 was consistent with our previous 
report [17]. The highest accumulation of both probes was observed in the kidneys, and 
moderate accumulation was observed in αvβ6 integrin-positive organs, such as the 
stomach and intestine. The uptake of [67Ga]CD6 in the AsPC-1 xenografts was 
significantly higher than that in the MIA PaCa-2 xenografts after 60 minutes, and the 
uptake of [67Ga]CD6 in the AsPC-1 xenografts was similar to that of [67Ga]CG6. 
Focusing on the uptake of both probes in the organs surrounding the pancreas, the 
uptake of [67Ga]CG6 in the liver and spleen was comparable to that in the AsPC-1 
xenografts. Conversely, the uptake of [67Ga]CD6 in the liver and spleen was 
significantly lower than that in the AsPC-1 xenografts after 60 minutes (P < 0.05, 
Mann-Whitney U-test). Compared to [67Ga]CG6, the uptake of [67Ga]CD6 in the liver 
and spleen was reduced by 73% (P = 0.057) and 83% (P < 0.05), respectively at 120 
minutes. 





Autoradiography and histological analysis 
 To confirm the in vivo specificity of [67Ga]CD6 toward αvβ6 integrin, we 
compared the areas of accumulated radioactivity with the β6 integrin-expressing areas 
in the tumors. Figure 3 shows the autoradiograms and β6 integrin immunostaining of 
each tumor section. With immunostaining, β6 integrin was strongly expressed in the 
AsPC-1 xenograft, while it was hardly detected in the MIA PaCa-2 xenograft. The areas 
of accumulated radioactivity in the autoradiogram of the AsPC-1 xenograft roughly 
coincided with the αvβ6 integrin-expressing areas. However, the areas where [67Ga]CD6 
accumulated in an independent manner of αvβ6 integrin expression were also observed 




 In the present study, we designed and synthesized [67Ga]CD6 to reduce the 
undesirable accumulation which would be derived from the positive charge of 
[67Ga]CG6. In vitro competitive binding assay revealed that the alteration of the linker 
between the N-terminus of A20FMDV2 and the cysteine residue had a negligible 




impact on the binding affinity to αvβ6 integrin. In the biodistribution study, the uptake 
of [67Ga]CD6 in the AsPC-1 xenografts was significantly higher than that in the MIA 
PaCa-2 xenografts at 60 and 120 minutes. The uptake of [67Ga]CD6 in the organs 
surrounding the pancreas was more than 2-fold lower than that of [67Ga]CG6 at both 
time points. This data suggested that [67Ga]CD6 overcame the drawbacks of [67Ga]CG6 
in its biodistribution. 
 The uptake of [67Ga]CD6 in almost all normal organs was at a similar level 
with that of [67Ga]CG6, except for in the liver and spleen. The uptake of [67Ga]CD6 in 
the liver and spleen was approximately 3.5-fold and 6-fold less than that of [67Ga]CG6, 
respectively, at 120 minutes. The cell membrane is generally negatively charged. 
Yamamoto et al. demonstrated that negatively charged micelles avoided non-specific 
accumulation in the liver and spleen, compared with neutral ones, which was 
attributable to the electrostatic repulsion [19]. Conversely, it was reported that highly 
negatively charged nanoparticles are easier to be opsonized than neutral and positively 
charged ones, and are easily taken up by macrophages in the reticuloendothelial system 
(RES) such as the liver and spleen [20]. However, Xiao et al. reported that nanoparticles 
with slightly negative charge showed the lowest uptake in the liver, and they estimated 
that it was attributed to not only the electrostatic repulsion but also the low opsonization 




rate [20]. Interestingly, a slightly negative charge has favorable effects on not only 
nanoparticles but also peptides. Other researchers reported that the introduction of the 
slightly negative charge to 99mTc-labeled bombesin analogues was one of the best way 
to reduce the liver uptake and improve their pharmacokinetic profile [21]. These results 
suggested that slightly negatively charged carriers could minimize the recognition and 
non-specific accumulation by macrophages in the RES. In this study, isoelectric point 
evaluation indicated that [67Ga]CD6 was more negatively charged than [67Ga]CG6. 
Therefore, the reduction of the [67Ga]CD6 uptake in the liver and spleen can be 
explained by the difference of the electric charge between [67Ga]CG6 and [67Ga]CD6. 
[67Ga]CD6 is the first radiolabeled A20FMDV2 derivative that charged negatively. Our 
findings may be contributing to the design of negatively-charged, novel A20FMDV2 
derivative probes. However, it is difficult to determine a preferable range of the electric 
charge of A20FMDV2-derived probes from our result. Garcia et al. evaluated the 
biodistribution of peptide probes that have various charges (+1, 0, -1, and -2). The 
radioactivity in the liver decreased in an amount-dependent manner of the negative 
charges [21]. The theoretical electric charge of [67Ga]CD6 was -3. From the viewpoint 
of liver accumulation, this value would meet a criterion because the liver accumulation 
of [67Ga]CD6 was more than 2-fold lower than that of [67Ga]CG6, with an electric 




charge of +3. Recently, we also succeeded in reduction of undesirable accumulation in 
the liver and spleen by N-acetylation of [67Ga]CG6 [17]. The theoretical net charge of 
acetylated [67Ga]CG6 (Ac-[67Ga]CG6) is +2. The accumulation of Ac-[67Ga]CG6 in the 
liver (0.26 ± 0.03 %ID/g at 120 minutes) and spleen (0.14 ± 0.01 %ID/g at 120 minutes) 
was at a similar level with that of [67Ga]CD6 in the liver and spleen at the same time 
point. As per tumoral accumulation, Ac-[67Ga]CG6 showed approximately 1.3-fold 
higher accumulation (2.02 ± 0.22 %ID/g at 120 minutes) than [67Ga]CD6 did. This 
finding is in accordance with the previously reported result by Garcia et al. that the 
most negatively charged probe did not show the best tumoral accumulation [21]. 
Therefore, it may be possible that the electric charge of -3 is too low to maintain the 
tumoral accumulation of [67Ga]CD6. To determine a preferable range of the electric 
charge, it is necessary to evaluate the biodistribution of A20FMDV2-derived probes 
with a charge from +1 to -2. 
 In the ARG study, there were some areas where [67Ga]CD6 accumulated 
independent of αvβ6 integrin expression. The accumulation of [67Ga]CD6 in such areas 
would be derived from the non-specific binding. The results of in vivo blocking studies 
performed previously indicated that the accumulation of A20FMDV2-derived probes in 
αvβ6-integrin-positive xenografts was not completely blocked. The percentage of 




radioactivity decrease was approximately 40-60% in the blocking group [3, 16, 17]. 
Therefore, [67Ga]CD6 may also have characteristics showing moderate non-specific 
binding. 
Previously, it was reported that Ga-complex conjugated oligo-aspartic acids, 
[67/68Ga]DOTA-(Asp)n, strongly bound to hydroxyapatite, a major component of the 
bone [22]. [68Ga]DOTA-D11-c(RGDfK) was also reported to be a potential PET probe 
for the diagnosis of primary cancer lesions, in addition to simultaneously diagnosing 
osteoblastic and osteolytic bone metastases [23]. Similar to these probes, [67Ga]CD6 
might allow for the visualization of primary cancer lesions and bone metastases. 
However, the bone uptake of [67Ga]CD6 was low (less than 1 %ID/g) at all time points 
examined, hence the D6 linker in [67Ga]CD6 was not of sufficient length to interact with 
hydroxyapatite in the bone. 
 A major problem of low molecular weight probes labeled by metallic 
radionuclides is the high and persistent radioactivity level in the kidneys [24]. 
Specifically, cationic probes will strongly interact with the brush border membrane on 
the proximal tubules because the membrane is negatively charged [21, 25]. In the 
previous study regarding [111In]DTPA-octreotide derivatives, the uptake of 
[111In]DTPA-Asp-D-Phe-octreotide in the kidneys was remarkably lower than that of 




[111In]DTPA-D-Phe-octreotide due to its negative charge [25]. In the current study, the 
uptake of [67Ga]CD6 in the kidneys was lower than that of [67Ga]CG6 at 60 and 120 
minutes after administration. Similar to [111In]DTPA-Asp-D-Phe-octreotide, this 
reduction of the renal radioactivity can be explained by the negative charge of 
[67Ga]CD6. However, renal radioactivity remained high and persistent. Therefore, the 
modification of the electric charges of [67Ga]CD6 alone was insufficient to reduce renal 
radioactivity. These results suggested that further improvements of [67Ga]CD6 to reduce 
the radioactivity in the kidneys are needed, such as the introduction of metabolizable 
linkers, such as NOTA-Met-Ile-maleimide or NOTA-Met-Val-Lys-maleimide [24, 26]. 
 Several PET probes based on the A20FMDV2 peptide have already been 
reported. Hausner et al. developed [18F]FBA-A20FMDV2 [12, 27] and 
[18F]FBA-PEG28-A20FMDV2-PEG28 [14], and both probes were potent αvβ6 integrin 
imaging agents, in vivo. Particularly, [18F]FBA-A20FMDV2 was evaluated in healthy 
human subjects and was confirmed safe [28]. The uptake of [67Ga]CD6 in the αvβ6 
integrin-positive xenografts (1.86 ± 0.34 %ID/g at 60 minutes) was superior to 
[18F]FBA-A20FMDV2 (0.69 ± 0.19 %ID/g at 60 minutes), but inferior to 
[18F]FBA-PEG28-A20FMDV2-PEG28 (4.7 ± 0.9 %ID/g at 60 minutes) [14, 27], 
although direct comparison was difficult because the biodistribution studies were 




conducted using different cell lines. Hausner et al. also reported that the bi-terminal 
PEGylation of A20FMDV2 improved not only its tumor retention but also its tumor 
uptake [14, 27]. In the current study, the N- and C-termini of [67Ga]CD6 were not 
modified by polyethylene glycol (PEG). Therefore, the bi-terminal PEGylation of 
[67Ga]CD6 should have favorable influences on its targeting capability. 
  [67Ga]CD6 highly accumulated in the stomach and intestine which were 
organs surrounding the pancreas. It is reported that αvβ6 integrin physiologically 
expresses strongly in mouse stomach and moderately in mouse intestine [16]. However, 
the first-in-human study of [18F]FBA-A20FMDV2 revealed that the radioactivity 
accumulation in the stomach and intestine was at a similar level as the liver and cleared 
lineally in a log-scale graph [28]. Therefore, PDAC might be detected by [67/68Ga]CD6 




 [67Ga]CD6 showed high binding affinity to αvβ6 integrin not only in vitro but 
also in vivo. Replacement of the linker amino acid from Gly to Asp provided a negative 
charge to the probe, resulting in the reduction of non-specific accumulation in the liver 




and spleen. The replacement of the linker amino acid did not affect tumoral 
accumulation of the probe. Therefore, [67Ga]CD6 overcame the drawbacks of 
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Table 1. Calculated and measured pI values of peptides 
Peptides Calculated pI † Measured pI 
H-Cys-(Gly)6-A20FMDV2-NH2 (CG6-A20FMDV2) 9.5 10-11 
H-Cys-(Asp)6-A20FMDV2-NH2 (CD6-A20FMDV2) 4.0 4-5 
†: The pI values were calculated by the ProtParam tool 
(https://web.expasy.org/protparam/), regarding the peptide sequence as 
H-Cys-X6-A20FMDV2-OH (X = Gly or Asp). 
  




Table 2. Biodistribution of [67Ga]CG6 and [67Ga]CD6 in tumor-bearing mice 
 10 min  60 min  120 min 
Organ [67Ga]CG6 [67Ga]CD6  [67Ga]CG6 [67Ga]CD6  [67Ga]CG6 [67Ga]CD6 
Blood 1.52 ± 0.57 1.11 ± 0.25  0.54 ± 0.11 0.46 ± 0.19  0.41 ± 0.11 0.22 ± 0.02 
AsPC-1 1.69 ± 0.32 2.01 ± 0.46  1.83 ± 0.40 1.86 ± 0.34†  1.18 ± 0.21 1.51 ± 0.24† 
MIA PaCa-2 2.06 ± 0.23 1.72 ± 0.75  0.55 ± 0.12 0.49 ± 0.10  0.57 ±0.06 0.35 ± 0.05 
Pancreas 2.96 ± 1.05 1.78 ± 0.42  0.87 ± 0.39 0.81 ± 0.12  0.86 ± 0.09 0.65 ± 0.05* 
Liver 1.64 ± 0.77 0.55 ± 0.07  1.03 ± 0.38 0.31 ± 0.05**  1.10 ± 0.50 0.30 ± 0.10 
Spleen 1.52 ± 0.88 0.49 ± 0.16  1.02 ± 0.48 0.49 ± 0.36  1.27 ± 0.60 0.21 ± 0.04* 
Heart 2.68 ± 0.28 1.73 ± 0.30  1.82 ± 0.25 1.27 ± 0.48*  1.29 ± 0.04 1.09 ± 0.06 
Lung 4.95 ± 1.25 3.32 ± 0.57  4.51 ± 0.79 1.84 ± 0.34**  3.26 ± 1.18 1.43 ± 0.21 
Muscle 2.39 ± 0.67 1.23 ± 0.32  2.07 ± 0.33 1.44 ± 0.14*  1.70 ± 0.38 1.29 ± 0.40 
Stomach 13.42 ± 3.62 19.01 ± 2.48  15.08 ± 2.88 17.85 ± 5.72  12.09 ± 2.16 13.48 ± 2.62 
Intestine 7.37 ± 1.45 11.90 ± 1.63  6.02 ± 1.34 9.35 ± 1.37*  5.58 ± 1.02 7.30 ± 0.36 
Kidney 85.84 ± 8.69 97.43 ± 3.99  128.02 ± 13.22 95.56 ± 13.31*  123.14 ± 16.18 109.13 ± 14.98 
Bone n.d. 0.89 ± 0.19  n.d. 0.54 ± 0.13  n.d. 0.52 ± 0.11 
Organ uptake values expressed as percent injected dose per gram of tissue. 
The bone uptake of [67Ga]CG6 was not measured at all time points examined (n.d., not 





Values are represented as mean ± S.D., n = 3-8. 
* and ** indicate P < 0.05 and P < 0.01 versus the uptake of [67Ga]CG6 at the same 
time points, respectively (Mann Whitney U-test). 
† indicates P < 0.05 versus the uptake of [67Ga]CD6 in the MIA PaCa-2 xenografts at 
the same points (Mann-Whitney U-test). 
  








Fig. 1  The Coomassie brilliant blue (CBB) stained strip gels containing 
CG6-A20FMDV2 (upper) and CD6-A20FMDV2 (bottom). 
The white and black arrowheads indicate the bands of CG6-A20FMDV2 and 
CD6-A20FMDV2, respectively. * indicates cracks caused by the electrodes, not the 
bands derived from the peptides. 
  






Fig. 2  Typical analytical HPLC chromatograms of [nat/67Ga]CG6 and [nat/67Ga]CD6. 
(a) HPLC chromatograms of [natGa]CG6 (left) and [67Ga]CG6 (right). The retention 
time of [natGa]CG6 and [67Ga]CG6 were 4.44 and 4.81 min, respectively. (b) HPLC 
chromatograms of [natGa]CD6 (left) and [67Ga]CD6 (right). The retention time of 
[natGa]CD6 and [67Ga]CD6 were 5.64 and 5.84 min, respectively.  
  






Fig. 3  Representative images of autoradiograms (ARG) and β6 integrin 
immunostaining in the AsPC-1 and MIA PaCa-2 tumor sections. 
β6 integrin only dimerized with αv integrin, and thus the β6 integrin-expressing areas 
are regarded as the αvβ6 integrin-expressing area. The β6 integrin-positive areas 
(brown) were roughly coincided with the radioactivity accumulation areas in the 
AsPC-1 xenograft. 
